CTLA4 and neoplasm: Malignancies in the hot tumour group have generally shown a better outcome in response to ICIs, such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 drugs; thus, an alternative therapeutic strategy for cold tumours needs to be explored further [16].